Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating

Krystal Biotech, Inc. (NASDAQ:KRYS) is among the 11 Best All-Time High Stocks to Buy According to Wall Street. On February 17, 2026, Jefferies analyst Roger Song raised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $371 from $310 and maintained a Buy rating. Roger Song noted another strong quarter and full year, with Vyjuvek and DEB U.S. revenue growth re-accelerating on robust demand and penetration reaching about 60%, while ex-U.S. expansion is expected to become a 2026 growth driver. Roger ...